Burnout Syndrome in urgency mobile service professionals

Objective: To analyze the prevalence of Burnout Syndrome in professionals of the Mobile Urgency Service. Methods: Descriptive, transversal and quantitative research, in which 32 professionals participated. The data were collected through the Maslach Burnout Inventory and analyzed using SPSS for Windows. The Research Ethics Committee under the CAAE No. 0040.0.045.000-11 approved the study. Results: For the team as a whole, there were high scores for Emotional Exhaustion (28,1%), Depersonalization (21,9%) and Professional Incompetence (28,1%) (reverse score). Among doctors, the Emotional Exhaustion and Depersonalization were higher when compared to the nursing staff; and Professional Incompetence scores were higher for nursing technicians. Conclusion: The increase in knowledge on the subject can contribute to the daily life of these professionals, since the syndrome was found among professionals of this study

Síndrome de burnout em profissionais do serviço de atendimento móvel de urgência Burnout Syndrome in urgency mobile service professionals

Objetivo: analisar a prevalência da Síndrome de Burnout em profissionais do Serviço de Atendimento Móvel de Urgência. Métodos: pesquisa descritiva, transversal e quantitativa, da qual participaram 32 profissionais. Os dados foram coletados por meio do Inventário Maslach de Burnout e analisados no SPSS for Windows. A pesquisa foi aprovada pelo Comitê de Ética em Pesquisa sob CAAE n° 0040.0.045.000-11. Resultados: para a equipe como um todo, houve escores altos para Desgaste Emocional (28,1%) Despersonalização (21,9%) e Incompetência Profissional (28,1%) (escore reverso). Na equipe médica, o Desgaste Emocional e Despersonalização foram maiores quando comparado a equipe de enfermagem; e em Incompetência Profissional os escores foram mais elevados para os técnicos de enfermagem. Conclusão: a produção de maior conhecimento sobre a temática pode contribuir no cotidiano destes profissionais, visto que a síndrome manifestou-se entre os profissionais do presente estudo. Descritores: Saúde do Trabalhador, Esgotamento Profissional, Serviços Médicos de Emergência

Síndrome de burnout em profissionais do serviço de atendimento móvel de urgência Burnout Syndrome in urgency mobile service professionals

Objetivo: analisar a prevalência da Síndrome de Burnout em profissionais do Serviço de Atendimento Móvel de Urgência. Métodos: pesquisa descritiva, transversal e quantitativa, da qual participaram 32 profissionais. Os dados foram coletados por meio do Inventário Maslach de Burnout e analisados no SPSS for Windows. A pesquisa foi aprovada pelo Comitê de Ética em Pesquisa sob CAAE n° 0040.0.045.000-11. Resultados: para a equipe como um todo, houve escores altos para Desgaste Emocional (28,1%) Despersonalização (21,9%) e Incompetência Profissional (28,1%) (escore reverso). Na equipe médica, o Desgaste Emocional e Despersonalização foram maiores quando comparado a equipe de enfermagem; e em Incompetência Profissional os escores foram mais elevados para os técnicos de enfermagem. Conclusão: a produção de maior conhecimento sobre a temática pode contribuir no cotidiano destes profissionais, visto que a síndrome manifestou-se entre os profissionais do presente estudo. Descritores: Saúde do Trabalhador, Esgotamento Profissional, Serviços Médicos de Emergência

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Síndrome de burnout em profissionais do serviço de atendimento móvel de urgência Burnout Syndrome in urgency mobile service professionals

Objetivo: analisar a prevalência da Síndrome de Burnout em profissionais do Serviço de Atendimento Móvel de Urgência. Métodos: pesquisa descritiva, transversal e quantitativa, da qual participaram 32 profissionais. Os dados foram coletados por meio do Inventário Maslach de Burnout e analisados no SPSS for Windows. A pesquisa foi aprovada pelo Comitê de Ética em Pesquisa sob CAAE n° 0040.0.045.000-11. Resultados: para a equipe como um todo, houve escores altos para Desgaste Emocional (28,1%) Despersonalização (21,9%) e Incompetência Profissional (28,1%) (escore reverso). Na equipe médica, o Desgaste Emocional e Despersonalização foram maiores quando comparado a equipe de enfermagem; e em Incompetência Profissional os escores foram mais elevados para os técnicos de enfermagem. Conclusão: a produção de maior conhecimento sobre a temática pode contribuir no cotidiano destes profissionais, visto que a síndrome manifestou-se entre os profissionais do presente estudo. Descritores: Saúde do Trabalhador, Esgotamento Profissional, Serviços Médicos de Emergência

Brazilian Flora 2020: Leveraging the power of a collaborative scientific network

International audienceThe shortage of reliable primary taxonomic data limits the description of biological taxa and the understanding of biodiversity patterns and processes, complicating biogeographical, ecological, and evolutionary studies. This deficit creates a significant taxonomic impediment to biodiversity research and conservation planning. The taxonomic impediment and the biodiversity crisis are widely recognized, highlighting the urgent need for reliable taxonomic data. Over the past decade, numerous countries worldwide have devoted considerable effort to Target 1 of the Global Strategy for Plant Conservation (GSPC), which called for the preparation of a working list of all known plant species by 2010 and an online world Flora by 2020. Brazil is a megadiverse country, home to more of the world's known plant species than any other country. Despite that, Flora Brasiliensis, concluded in 1906, was the last comprehensive treatment of the Brazilian flora. The lack of accurate estimates of the number of species of algae, fungi, and plants occurring in Brazil contributes to the prevailing taxonomic impediment and delays progress towards the GSPC targets. Over the past 12 years, a legion of taxonomists motivated to meet Target 1 of the GSPC, worked together to gather and integrate knowledge on the algal, plant, and fungal diversity of Brazil. Overall, a team of about 980 taxonomists joined efforts in a highly collaborative project that used cybertaxonomy to prepare an updated Flora of Brazil, showing the power of scientific collaboration to reach ambitious goals. This paper presents an overview of the Brazilian Flora 2020 and provides taxonomic and spatial updates on the algae, fungi, and plants found in one of the world's most biodiverse countries. We further identify collection gaps and summarize future goals that extend beyond 2020. Our results show that Brazil is home to 46,975 native species of algae, fungi, and plants, of which 19,669 are endemic to the country. The data compiled to date suggests that the Atlantic Rainforest might be the most diverse Brazilian domain for all plant groups except gymnosperms, which are most diverse in the Amazon. However, scientific knowledge of Brazilian diversity is still unequally distributed, with the Atlantic Rainforest and the Cerrado being the most intensively sampled and studied biomes in the country. In times of “scientific reductionism”, with botanical and mycological sciences suffering pervasive depreciation in recent decades, the first online Flora of Brazil 2020 significantly enhanced the quality and quantity of taxonomic data available for algae, fungi, and plants from Brazil. This project also made all the information freely available online, providing a firm foundation for future research and for the management, conservation, and sustainable use of the Brazilian funga and flora